ADTX - Aditxt Inc.  logo

ADTX

Aditxt Inc.

Rev โ€”top 1%5Y
Hold

Aditxt Inc. develops immune health products, including AditxtScore for personalized immune profiling and Apoptotic DNA Immunotherapy to retrain the immune system. The company focuses on addressing autoimmune diseases, organ rejection, and therapeutic innovations.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth-1249x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth23x
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-4708x
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend60%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-4708x
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend60%
Revenue Consistency

See the full market ranking โ†’

Aditxt Inc. fundamental performance

Across Aditxt Inc. 's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 3M and net income went from -$ 9M to -$ 43.10B. Revenue increased in 60% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.00โ€”
1 Year2025-08-12
$ 25.14K-100.00%
5 Years2021-08-12
$ 1000K-100.00%
All Time2020-06-30
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 3M-$ 43.10B$ 3.19B
2024$ 133.99K-$ 34M$ 833M
2023$ 645.18K-$ 32M$ 97.1K
2022$ 933.72K-$ 27M$ 2M
2021$ 105.03K-$ 46M$ 7M
IPO2020$ 0.00-$ 9M$ 10M

Explore beyond ADTX

You're looking at Aditxt Inc. . Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies